Innovative Techniques and TechnologyLifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease
Under a Creative Commons license
open access
Key Words
dry eye disease
ICAM-1
inflammation
integrin antagonist
LFA-1
lifitegrast
Abbreviations
+
Positive
APC
Antigen-presenting cell
CYP450
Cytochrome P450
DED
Dry eye disease
IC50
Half maximal inhibitory concentration
ICAM-1
Intercellular adhesion molecule 1
ICSS
Inferior corneal staining score
IFN
Interferon
IL-1
Interleukin 1
IS
Immunological synapse
LFA-1
Lymphocyte function-associated antigen 1
MMP
Matrix metalloproteinase
PK
Pharmacokinetic
SD
Standard deviation
TH
T helper cell
TNF
Tumor necrosis factor
Treg
Regulatory T cell
Cited by (0)
Shire provided funding for medical writing assistance. The authors had responsibility for the collection, analysis, and interpretation of source articles; the writing of the manuscript; and the decision to submit the manuscript for publication. Shire reviewed the manuscript for accuracy.
Dr. Perez is a scientific advisor for Shire, Bausch & Lomb, Eyegate, and Eleven Biotherapeutics.
Dr. Pflugfelder is a consultant for Shire. Drs. Zhang, Shojaei, and Haque are employees of Shire and own stock and stock options in Shire.
Single-copy reprint requests to Victor L. Perez, MD (address below).
© 2016 The Authors. Published by Elsevier Inc.